Droia invests globally in young drug development companies that use novel science and innovative approaches to bring promising therapies to patients. We are specialists, investing exclusively in therapeutics for oncology and genetic disease.
Our focus and our in-house team of drug development experts and biotech professionals allow us to accelerate our companies’ progress by actively supporting them from company creation through clinical proof of concept. We are hands-on investors and entrepreneurs, fully dedicated to making an impact and saving patient lives.
Breakthrough focus
For biotech companies, ultimate success is measured in effective patient benefit. Promising therapies should have a material impact on patient prognosis, measured as a function of the severity of the unmet medical need addressed and the improvement in therapeutic benefits as compared to (expected) standard of care.
We only invest in companies that are able, through their technology platforms or scientific insights, to go after previously unsolvable clinical problems. Companies should differentiate not only by way of innovation, but also in the way this innovation translates to clinical breakthrough.
Getting it done
Droia actively scouts for the best science and the best teams. Whether investing in an existing company or creating a new company, we actively participate in our portfolio companies’ development. Our team has deep and specialized experience in disease biology, translational science, clinical development and company building.
We have built many companies from the ground up, supporting and complementing founders and management teams. Our team members dedicate their time to helping their companies, and will take on interim roles within companies to help them get off the ground faster. Our whole organization is geared towards doing what we do best: building great drug development companies.
Portfolio
Arcus Biosciences (Hayward, California; NYSE:RCUS) develops small-molecules and antibodies to compose proprietary immune-oncology combinations. The company targets tumor related immune suppression, enhanced APC function and immune cell efficacy. — Arcusbio.com
Aura Biosciences (Cambridge, Massachusetts) develops tumor targeted viral-like nanoparticles which can encapsulate a wide range of payloads. Aura’s lead product is in clinical trials against ocular melanoma. — Aurabiosciences.com
Cristal Therapeutics (Maastricht, The Netherlands) develops a polymeric nanoparticle drug delivery platform enhancing the PK properties of chemotherapeutic or nucleotide payloads and improving their uptake in the tumor microenvironment. — Cristaltherapeutics.com
Cyteir Therapeutics (Lexington, Massachusetts) is developing the next generation of synthetic lethal therapies to treat cancer and autoimmune disease. — Cyteir.com
Frontier Medicines (South San Francisco, California) leverages chemoproteomics and machine learning to accelerate the development of medicines that drug the “undruggable” protein targets that drive human disease. — Frontiermeds.com
Highlight Therapeutics (Madrid, Spain) develops nanocomplexes of synthetic dsRNA that target PAMP receptors and TLRs to induce powerful immune responses. Bioncotech is clinically evaluating several immune-oncology combinations with its lead product. — Highlighttherapeutics.com
Montis Biosciences (Leuven, Belgium) develops novel immuno-oncology therapeutics targeting the intersection between perivascular macrophages and tumor vasculature — Montisbiosciences.com
Octimet (Beerse, Belgium) is developing a new generation of highly selective MET kinase inhibitors with augmented therapeutic index. The lead compound was licensed from J&J and is being clinically tested in specific MET mutated patient populations. — Octimet.com
PACT Pharma (Hayward, California) develops neoantigen-specific adoptive TCR T-cell therapies. PACT’s proprietary neoantigen identification technology advances the feasibility, potency and affordability of personalized cell therapy for cancer. — Pactpharma.com
QurAlis (Cambridge, Massachusetts) develops new therapies against amyotrophic lateral sclerosis (ALS), the most common form of adult motor neuron disease. – Quralis.com
Tusk Therapeutics (Stevenage, UK – acquired by Roche) is developing novel immune modulating antibodies based on an in-depth understanding of the innate and adaptive immune system. — Tusktherapeutics.com
Vico Therapeutics (Leiden, The Netherlands) works on RNA modulating therapies for rare neurological disorders, developing antisense oligonucleotide against spinocerebellar ataxia, Huntington’s disease and RETT syndrome. – vicotx.com
Volastra Therapeutics (NY, USA) targets chromosomal instability to tackle metastases and therapeutic resistance. — Volastratx.com
People
- M.Sc. Engineering, University of Leuven
- MBA, INSEAD
- McKinsey & Company
- Waterland Private Equity
* representing Wepaven BV
Janwillem Naesens *
Managing Partner, Oncology & Droia Group
- Pharm.D., University of Leuven
- MBA, Vlerick Management School
- Arthur D. Little
- TiGenix
- Prosensa
- Tusk Therapeutics
- Independent board member Erytech, Pharvaris
* representing Primix Bio Ventures BV
Luc Dochez *
Managing Partner, Genetic Disease
- M.Sc. Bio-Engineering, University of Leuven
- Founder / former owner of Verelst real estate group
- Seasoned investor in small and big biotech, venture capital
- Founder of the Anti Cancer Fund and the Verelst Uterine Cancer Fund
Luc Verelst
Founder & Chairman
- BA in Biology, University of Virginia
- PhD in Genetics, University of Wisconsin-Madison
- Novartis
- Celgene (Bristol Myers Squibb)
- Arch Venture Partners
- Board member Acceleron Pharma, Sage Therapeutics, Carrick Therapeutics, Shattuck Labs and others
George Golumbeski
Partner
- BA in Biochemistry, Catholic University in Chile
- PhD in Cell Biology, UCSF
- Medivation
- Praxis Biotech
- Merken Biotech
Sebastian Bernales
Venture Partner
- Group leader at the Netherlands Cancer Institute
- Head of the NKI Robotics and Screening Center
- Expert in large scale functional genomics
- Pioneer of pooled screening technology
- Co-founder of Qameleon Therapeutics
Roderick Beijersbergen
Investment Advisory Board
- Msc. Business Engineering, Université Catholique de Louvain
- Executive Master in Finance, Solvay Business School
- ING Bank, Corporate Banking
- Floridienne Group, CFO
* representing Axis Advice SRL
Lionel de Hemptinne *
Chief Financial Officer
Nathalie De Blieck
Reporting & Accounting Specialist
- Master of laws, University of Leuven
- M.Sc. law and finance, Oxford University and Saïd Business School
- Cleary Gottlieb Steen & Hamilton
- Freshfields Bruckhaus Deringer
- Etex Group
* representing MARA Consulting BV
Matthias De Witte *
General Counsel
- MSc Cancer, University College London
- PhD Biomedical Sciences, University of Leuven
- Doctoral research in Angiogenesis and Vascular Metabolism lab, VIB
- FWO PhD Fellowship
- The UCL Cancer Institute Research Trust and Athena SWAN award for Excellence in Science 2014
Pauline De Zeeuw
Scientific Analyst
Sara Morren
HR & Office Manager – Executive Management Assistant
- PhD in Biomedical Sciences, University of Leuven
- Doctoral Researcher in Alzheimer's disease, VIB
- M.Sc. Biochemistry and Biotechnology, University of Antwerp
- Master Thesis, MolGen department, VIB
- Internship Master, diagnostic tests for breast cancer, Multiplicom NV Niel
Dieter Petit
Scientific Analyst Genetic Diseases
- Professor of Cancer Immunology and Immunotherapy at UCL Cancer Institute
- Group Leader of the Immune Regulation and Tumour Immunotherapy Laboratory
- CRUK Senior Cancer Research Fellow
- Co-leading scientist CRUK Cancer Immunotherapy Accelerator
- CSO at Achilles Therapeutics
Sergio Quezada
Investment Advisory Board
- Executive Chairman of RGenix, Inc
- Board Member at Biogen, Navidea, Fortress Biotech, Verastem
- Chief Medical Office/Scientific Advisor: Hummingbird Biosciences, Oncotartis, Lokon
- Oncology Advisor, Everest Medicines
Eric Rowinsky
Investment Advisory Board
- M. Sc. Biomedical Sciences, University of Leuven
- PhD Biomedical Sciences – Angiogenesis and Metabolism, University of Leuven
- Starter Fellowship Emmanuelle van der Schueren, VLK
- PhD fellow IWT & Post-doc fellow FWO
- Nominee Eos Pipet
- Recipient BiR&D Multidisciplinary PhD Award
* representing Sascon BV
Sandra Schoors *
Associate Partner
- Professor in the Department of Neurosciences at KU Leuven
- Group leader at the VIB Center for Brain & Disease Research.
- Head of the Laboratory of Neurobiology at VIB
- Scientific Founder of Augustine Therapeutics
Ludo Van Den Bosch
Investment Advisory Board
- Associate Professor in the Department of Biology at the Massachusetts Institute of Technology
- Associate Director of the Koch Institute for Integrative Cancer Research
- Institute Member of the Broad Institute of Harvard and MIT
- Instructor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School
Matthew Vander Heiden
Investment Advisory Board
- PhD Medical Sciences, DNA damage in cancer, University of Cambridge, UK
- Postdoctoral Fellow, novel drug targets in a rare cancer, New York University Langone Health, USA
- Recipient Cancer Research UK PhD Fellowship
- Scientific publications in e.g. JNCI, Oncotarget, Eur J Hum Genet
Elke van Oudenhove
Scientific Analyst
- M. Sc. Biomedical Sciences, University of Leuven
- PhD Biomedical Sciences – Tumor Immunology, University of Leuven
- PhD Pharmaceutical Sciences – Polymers, ULB
- PhD fellow IWT
- Recipient VCU RDD Peter R. Byron Graduate Student Award
- Belgian Brain Tumor Support
Matthias Van Woensel
Principal
- MSc. Business Engineering, University of Leuven
- CFA – level I
- Ernst & Young, M&A advisory
- Corporate finance, M&A, BD, structuring, tax & legal, modeling & valuation
- Tusk Therapeutics, interim CFO
Joke Vereecken
PrincipalNews
-
11Feb
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
“We are intrigued by the potential of RAD-51 inhibition, particularly due to early findings suggesting it could be helpful in treating lymphomas and other hematologic malignancies,” said Derek DiRocco, Ph.D., partner, RA Capital Management. “This pro...
-
05Jan
Aura Biosciences Appoints David Johnson to Its Board of Directors
With David’s impressive track record in oncology and as an accomplished CEO, his engagement and guidance will help Aura drive AU-011 for the treatment of choroidal melanoma to registration and commercialization,” said George Golumbeski, Ph.D., Chairm...
-
11Dec
QurAlis’ selective Kv7 opener, a drug candidate for ALS, demonstrates up to 20-fold increase in potency and dramatic reduction in side effects compared to Retigabine in preclinical models
QurAlis' announces the results of extensive pre-clinical studies on its lead program for ALS patients: QRA-244 shows comparable effects to retigabine and dramatic reductions in side effects....
Careers
Droia is currently recruiting for its investment and development team. The team scouts for new opportunities, evaluates companies and projects, manages the investment and exit process, and works with the portfolio companies on their progress.
Team members work closely with the portfolio companies at management or board level, and play a hands-on role in all aspects of the drug development process.
Droia is an entrepreneurial environment, where everyone is above all committed to making things happen.
Applicants should have relevant experience in biomedical science, drug development and/or life science investing.